Clinical Development Failure Risk: The company's products are in various stages of development, and there is no guarantee that they will successfully complete clinical trials or demonstrate efficacy and safety, which could lead to project abandonment or significant delays.

Regulatory Approval Delays or Denial Risk: Microbot Medical's success hinges on obtaining and maintaining regulatory approvals (e.g., FDA, CE Mark) for its devices. These processes are lengthy, costly, and uncertain, and any failure or delay could prevent products from reaching the market.

Insufficient Capital and Funding Dilution Risk: Developing and commercializing medical devices is capital-intensive. The company may need additional financing, which could be difficult to obtain or could result in significant dilution for existing shareholders if raised through equity.